Psychiatric shades of grey: mirtazapine-induced hair discoloration and hair loss

2016 ◽  
Vol 33 (3) ◽  
pp. 175-178 ◽  
Author(s):  
M. Osman ◽  
M. D. McCauley

IntroductionMirtazapine is indicated in the treatment of major depressive disorder particularly in selective serotonin re-uptake inhibitors resistance. Its effect on hair loss is rare with no previous documented effect on hair colour.MethodReview of relevant literature and description of a case report of a 54-year-old male patient who developed alopecia and hair discoloration after initiation of mirtazapine treatment.ResultsUpon cessation of mirtazapine treatment full restoration of hair colour and regrowth of hair was attained within 10 weeks.DiscussionThere was clear temporal relationship between experiencing hair loss and commencing mirtazapine treatment. No other more likely medical reason to explain such experience was established. A noticeable restoration of the hair colour occurred following mirtazapine cessation.ConclusionMirtazapine is associated with hair discoloration and hair loss. The possibility of such distressing adverse effects needs to be conveyed to patients by clinicians and to be further explored by researchers.

2020 ◽  
Vol 2 (3-4) ◽  
pp. 281-283
Author(s):  
Roshan Sutar ◽  
Faisal Siddiqui ◽  
Abin Rajan

Commonly prescribed antidepressants are associated with sexual adverse effects predominantly reported as erectile dysfunction by men. The clinical dilemma of choosing the right antidepressant while not compromising the sexual functioning is an area of recent research. Few antidepressants, namely dapoxetine, bupropion, trazodone, and mirtazapine, have been reported to have minimal sexual adverse effects. Vortioxetine is a relatively newer antidepressant with clinical profile having minimal sexual and cognitive adverse effects. However, improvement in sexual dysfunction after treatment with vortioxetine has not been reported so far. We highlight the unique benefit of vortioxetine in improving sexual dysfunction in a case of major depressive disorder.


2014 ◽  
Vol 75 (12) ◽  
pp. e23-e26 ◽  
Author(s):  
Souhel Najjar ◽  
Daniel M. Pearlman ◽  
Scott Hirsch ◽  
Kent Friedman ◽  
John Strange ◽  
...  

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
N. Zivkovic ◽  
G. Djokic ◽  
D. Pavicevic ◽  
V. Ilic

Major depressive disorder (MDD) is common and severe affective disorder with sleep disturbances and non-bizarre delusions which are organized in permanent and unshakeable delusional system. Neurobiological basis of MDD is still completely unknown, but significant role has serotoninergic and noradrenergic neuronal systems. Escitalopram is highly potent and highly selective serotonin re-uptake inhibitor.Purpose of this study was to estimate efficacy of the escitalopram in treatment of sleep disturbances in MDD.Methods:This prospective clinical study included 95 patients diagnosed by ICD-10 criteria for MDD, who are randomly divided into control (30 patients) and experimental group (65 patients). Patients were observed for 6 months in hospital and outpatients conditions, according to specially designed protocol, which included Hamilton Depression Rating Scale (HAMD) and Leeds Sleeping Evaluation Questionnaire (LSEQ). Control group was treated with maprotiline (75-150 mg/24h) and experimental group with escitalopram (10-20 mg/24h).Results:Escitalopram therapy influenced on HAMD score with high statistical significance vs. maprotiline, p=0.000. Escitalopram therapy improves LSEQ score after 6 months in comparison to maprotiline therapy with high statistical significance p=0.000. Percentage of adverse effects is significantly lower in escitalopram (10.76%) than in maprotiline (26.67%) group.Conclusion:Escitalopram has significantly better efficacy and lower adverse effects rate in treatment of depressive symptoms and sleep disturbances in MDD patients comparing to maprotiline.


Sign in / Sign up

Export Citation Format

Share Document